Christopher Mohr

Title: Christopher Mohr: Innovator in Biopharmaceuticals

Introduction

Christopher Mohr is a distinguished inventor based in Newbury Park, CA (US). He has made significant contributions to the field of biopharmaceuticals, holding a total of 7 patents. His work primarily focuses on the development of innovative therapeutic solutions.

Latest Patents

One of his latest patents is titled "Bispecific antibodies with cleavable C-terminal charge-paired tags." This invention involves a CH3-containing molecule that includes a first polypeptide with a CH3 domain and a negatively charged domain, as well as a second polypeptide with a CH3 domain and a positively charged domain. The patent also outlines methods for conjugating synthetic molecules to a multi-specific antigen binding molecule. Another notable patent is related to "Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1)." This invention focuses on neutralizing antibodies for PAC1 and includes methods for treating or preventing headache conditions, such as migraines and cluster headaches.

Career Highlights

Christopher has worked with prominent companies in the biopharmaceutical sector, including Amgen Inc. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking innovations in the field.

Collaborations

Throughout his career, Christopher has collaborated with notable professionals, including Neeraj Jagdish Agrawal and Kevin Graham. These partnerships have further enhanced his research and development efforts.

Conclusion

Christopher Mohr is a remarkable inventor whose work in biopharmaceuticals continues to impact the industry significantly. His innovative patents and collaborations reflect his dedication to advancing medical science.